Login to Your Account

Ulcerative Colitis the Target

Alizyme, Norgine Team Up in $67M Marketing Deal

By Nuala Moran

Monday, June 30, 2008
LONDON - Alizyme plc landed the speciality pharma company Norgine BV as a European marketing partner for Colal-Pred, its treatment for ulcerative colitis. The deal has a headline value of €42.75 million (US$67.4 million), of which €2 million will be paid up front. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription